|Former Common name||Card15 KO (C57BL/6N background)|
|H-2 Haplotype||No Data|
|Background strain||No Data|
|Strain development||Developed by Marco Giovannini, INSERM. PGK-hygromycin cassette was removed by cre recombinase.|
|Strain description||This mouse was produced from the knock-in targeting of Card15 (Nod2) locus with EGFP cassette. The expression of the GFP is relatively low. C57BL/6 congenic (RBRC01869), C57BL/6 and 129 mixed background (RBRC01941).|
|Colony maintenance||Homozygote x Homozygote|
|Symbol name||caspase recruitment domain family, member 15|
|Common name||F830032C23Rik, IBD1, Nod2|
|Symbol description||No Data|
|Symbol name||Enhanced Green Fluorescent Protein, F64L and S65T (Jellyfish)|
|Common name||No Data|
|Symbol description||No Data|
|Research applications||Fluorescent Proteins/lacZ System,
Immunology and Inflammation Research,
Mouse Models for Human Disease
|Specific Term and Conditions||The following terms and conditions will be requested by the DEPOSITOR.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the “Invention”) RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR’s internal use.
RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party’s inventiveness contribution in the Invention.
In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters.
|1||Mouse of the Month Jun 2007|
|2||GFP Transfer License (Japanese / English)
Please fill in the Schedule A, and submit two signed copies to us together with two signed copies of RIKEN BRC’s MTA. Please also read Schedule B.
|3||Genotyping protocol <PCR>|
|Depositor||Giovannini, Marco (House Ear Institute)|
|Strain Status /
|NOD2 deletion promotes cardiac hypertrophy and fibrosis induced by pressure overload.||Lab Invest.93(10): 1128-36 (2013).(23958879)|
|Zong J, Salim M, Zhou H, Bian ZY, Dai J, Yuan Y, Deng W, Zhang JY, Zhang R, Wu QQ, Tang QZ.|